The news that Xeris Biopharma is expecting to reach the higher end of its revenue guidance is positive, as it exceeds the average analyst estimate. This suggests that the company is performing well financially. Additionally, the anticipation of becoming cash flow positive in Q4 is a strong indicator of financial health and may lead to increased investor confidence. Both pieces of information are likely to be viewed positively by the market, potentially leading to a short-term increase in the stock price.